Afrezza® Clinical Information

Abstracts, Posters and Publications

2016

PK and PD Properties of a Novel Inhaled insulin

J Diabetes Sci Technolo. 2016

View Publication

 

Improving efficacy of inhaled TI (Afrezza) by postmeal dosing: In silico clinical trial with the University of Virginia/Padova Type 1 Diabetes Simulator

Diabetes Technol Ther. 2016

View Publication

 

Technosphere® Insulin Inhalation Powder (TI) Displays Earlier Onset and Shorter Duration than Insulin Lispro (Lispro)

ADA 2016, poster 100-LB

View Publication

 

Within-Subject Variability of Insulin Exposure and Metabolic Activity Following Replicate Doses of Technosphere® Insulin Inhalation Powder (TI) in Patients with T1DM

ADA 2016, poster 102-LB

View Publication

 

Effects of Inhaled Technosphere Insulin (TI) on the Pulmonary Function of Patients with T1D and T2D

ADA 2016, poster 937-P

View Publication

 

The Impact of Baseline Lung Function on Outcomes With Inhaled Technosphere Insulin

ADA 2016, poster 973-P

View Publication

 

Technosphere® Inhaled Human Insulin has a More Rapid Onset of Action Than Subcutaneous Insulins – Meta Analysis of Clamp Data From Three Clinical Studies

ADA 2016, poster 931-P

View Publication

 

A Population PK/PD Model of Technosphere® Insulin Administered to Healthy Subjects

ADA 2016, poster 975-P

View Publication

 

Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere® Inhaled Insulin

BMJ Open Diabetes Research and Car 2016; 4:e000228

View Publication

 

Impact of Upper Respiratory Tract Infection on the Safety of Technosphere® Inhaled Insulin in Patients with Type 1 or Type 2 Diabetes

AACE 2016

View Publication

2015

Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents

Diabetes Care 2015 Dec. 38(12):2274-81

View Publication

 

Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial

Diabetes Care 2015 Dec. 38(12):2266-73

View Publication

 

Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation

AAPS PharmSciTech, 2015 Dec. 16(6):1299-306

View Publication

 

Reduced Hypoglycemia is Observed with Inhaled Insulin Versus Subcutaneous Insulin Aspart in Patients with Type 1 Diabetes Mellitus

AACE 2015, poster 1220

View Publication

 

Patient Level Assessment of Cough with TI in Patients with T1DM

Diabetes Technology Meeting 2015

View Publication

 

Inhalation of Insulin: Effect of Symptomatic Upper Respiratory Tract Infections on Pharmacokinetic/Pharmacodynamic (PK/PD) Properties

ADA 2015, Poster 94-LB

View Publication

 

Reduced Hypoglycemia is observed with Inhaled Insulin Versus Subcutaneous Insulin Aspart in Patients with Type 1 Diabetes Mellitus

EASD 2015

View Publication

 

2013

A Phase 1, Open-Label, Randomized Dose Proportionality Study of Technosphere Insulin Inhalation

ADA 2013, Poster 982-P

View Publication

 

Device factors affecting pulmonary delivery of dry powders.

Ther Deliv 2013 Aug;4(8): 939-49

View Publication

2012

Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere® Insulin or usual antidiabetes treatment: A randomized trial.

Diabetes, Obesity and Metabolism 2012;14:163-173

View Publication

 

Technosphere® insulin effectively controls postprandial glycemia in patients with T2 Diabetes Mellitus.

Diabetes Technology and Therapeutics 2012;14:997-1001

View Publication

 

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE. Acute bronchospasm has been observed in patients with asthma and COPD using AFREZZA. AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD. Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients.

Indications and Usage

AFREZZA® (insulin human) inhalation powder is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Limitations of Use

  • AFREZZA is not a substitute for long-acting insulin. AFREZZA must be used in combination with long-acting insulin in patients with type 1 diabetes mellitus.
  • AFREZZA is not recommended for the treatment of diabetic ketoacidosis.
  • The safety and efficacy of AFREZZA in patients who smoke has not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking (less than 6 months).

Important Safety Information

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE

  • Acute bronchospasm has been observed in patients with asthma and COPD using AFREZZA.
  • AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD.
  • Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients.

Access the AFREZZA Risk Evaluation and Mitigation Strategy (REMS) program at www.afrezzarems.com.

Contraindications

AFREZZA is contraindicated in patients:

  • During episodes of hypoglycemia.
  • With chronic lung disease (such as asthma or chronic obstructive pulmonary disease [(COPD)] because of the risk of acute bronchospasm.
  • With hypersensitivity to regular human insulin or any of the AFREZZA excipients.

Warnings and Precautions

Acute Bronchospasm: Prior to initiating therapy, evaluate patients with a medical history, physical examination and spirometry (FEV1) to identify potential underlying lung disease. Acute bronchospasm has been observed following AFREZZA dosing in patients with asthma and patients with COPD. The long-term safety and efficacy of AFREZZA in patients with chronic lung disease has not been established.

Change in Insulin Regimen: Monitor blood glucose in all patients treated with insulin. Modify insulin regimen and dose cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin therapy, including AFREZZA, and may be serious and life-threatening. Educate patients and caregivers on mitigating the risks associated with hypoglycemia.

Decline in Pulmonary Function: AFREZZA has been shown to cause a decrease in lung function as measured by FEV1. In clinical trials lasting up to 2 years, AFREZZA treated patients experienced a small (40 mL) but greater FEV1 decline than comparator treated patients. Assess pulmonary function with spirometry at baseline, after the initial 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. If symptoms persist, discontinue AFREZZA.

Lung Cancer: In clinical trials, 2 cases of lung cancer were reported in patients exposed to AFREZZA while no cases were reported for the comparators. Two additional cases of lung cancer (squamous cell) were reported in non-smokers exposed to AFREZZA after the trial completion. These data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of AFREZZA outweigh the risks.

Diabetic Ketoacidosis (DKA): Increase the frequency of glucose monitoring and consider an alternate route of administration of insulin in patients at risk for DKA.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue AFREZZA, monitor and treat if indicated.

Hypokalemia: Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs): Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of TZDs and insulin. Observe these patients for signs and symptoms of heart failure. If heart failure occurs, consider dose reduction or discontinuation of TZD.

Drug Interactions

Certain drugs may affect glucose metabolism, increasing the risk of hypoglycemia or decreasing the blood glucose lowering effect of AFREZZA. Dose adjustment and increased frequency of blood glucose monitoring may be required. Co-administration of beta-blockers, clonidine, guanethidine, and reserpine with AFREZZA may reduce the signs and symptoms of hypoglycemia.

Adverse Reactions

The most common adverse reactions associated with AFREZZA include hypoglycemia, cough, and throat pain or irritation.